Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal toxicity after radionuclide therapy.

Bieke Lambert1, Markus Cybulla, Stefan M Weiner

  • 1Division of Nuclear Medicine, Ghent University Hospital, Gent, Belgium.

Radiation Research
|May 27, 2004
PubMed
Summary

Radiolabeled peptides used in cancer therapy can cause kidney damage. Co-infusion with positively charged amino acids shows promise in preventing this radiation-induced renal damage, improving treatment safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pathophysiology of weather sensitivity - an overview].

MMW Fortschritte der Medizin·2026
Same author

Eryhtropoetin induced <sup>18</sup>F-PSMA-11 bone marrow sink effect.

European journal of nuclear medicine and molecular imaging·2026
Same author

Impact of single photon emission computed tomography/computed tomography bone scintigraphy on the clinical management of patients with recurrent pain post spinal fusion.

Nuclear medicine communications·2026
Same author

Impact of SGLT2 inhibitors in patients with Fabry disease.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease.

Frontiers in immunology·2026
Same author

Clinical Image-Based Dosimetry of Actinium-225 in Targeted Alpha Therapy.

Cancers·2026

Area of Science:

  • Oncology
  • Radiopharmaceuticals
  • Nephrology

Background:

  • Radiolabeled molecules (antibodies, fragments, peptides) are used for targeted cancer therapy.
  • High kidney localization of these agents raises concerns about renal radiation toxicity.
  • Yttrium-90 labeled somatostatin analogues highlight safety profile discussions for radiolabeled peptides.

Purpose of the Study:

  • To review the literature on nephrotoxicity following radiolabeled peptide therapy.
  • To discuss therapeutic options for preventing radiation-induced renal damage.
  • To explore insights into the pathogenic mechanisms of renal toxicity.

Main Methods:

  • Literature review of studies on radiolabeled peptide therapy and renal toxicity.
  • Analysis of factors influencing toxicity, including molecular characteristics and radionuclide properties.

Related Experiment Videos

  • Evaluation of protective strategies, such as amino acid co-infusion.

    • Main Results:

    • Renal toxicity is a significant concern in radiolabeled peptide therapy.
    • Toxicity risk is influenced by the properties of the radiolabeled molecule and the radionuclide.
    • Co-infusion of positively charged amino acids demonstrates encouraging results in preventing renal damage.

    Conclusions:

    • Understanding pathogenic mechanisms is crucial for developing safer radiolabeled peptide therapies.
    • Positively charged amino acid co-infusion represents a promising strategy to mitigate nephrotoxicity.
    • Further research into protective measures can enhance the therapeutic effectiveness and safety of targeted radionuclide therapy.